Principal Investigator
James Hoffman
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241070
Clinical Trial Summary
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647